Browsing by Author "Barutca, Sabri"

Now showing 1 - 3 of 3

Citation - WoS: 7
Citation - Scopus: 8
Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients With Metastatic Colorectal Cancer?
(Springer, 2021-04-21) Erdogan, Atike Pinar; Ekinci, Ferhat; Karabas, Aykut; Balcik, Onur Yazdan; Barutca, Sabri; Dirican, Ahmet
Purpose To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib. Methods A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated. Results According to the cut-off points, patients were divided into two groups. The patients in the high IPI group showed poorer OS compared to patients in the low IPI groups. The PFS was better in patients with low neutrophil-lymphocyte ratio (NLR) and platelet-neutrophil to lymphocyte ratio (PNLR), and the OS was better in patients with low IPI. Conclusion Among the immune inflammation scores analyzed in mCRC patients receiving regorafenib, NLR and PNLR were the best predictor of recurrence, whereas IPI was the best predictor of long-term survival. After being confirmed by better designed controlled trials, IPI can be used to identify the group of patients who will benefit more from regorafenib treatment.
Citation - WoS: 2
Citation - Scopus: 2
The Efficacy of Hddpiw-Jsb Solution on Docetaxel-Induced Alopecia of Rats
(Taylor & Francis Ltd, 2024-01-05) Demir, Bilgin; Demirci, Buket; Tataroglu, Canten; Barutca, Sabri; Barutca, Duygu
ObjectiveChemotherapy induced alopecia (CIA) is one of the most common side effects in cancer patients, however; it doesn't have an effective pharmacological treatment yet. In this study we aimed to research the protective effect of newly developed HDDPiW-jSB solution on docetaxel (DTX) -induced rat alopecia model.Material and MethodsDocetaxel (10 mg/kg/week) was administered to the 6-8 months old rats for three weeks. HDDPiW-jSB solution was applied once or twice a week for 4 weeks beginning prior to one week before DTX. Rat hair follicles were evaluated with hematoxylin-eosin and immune-histochemical staining.ResultsIn the first stage of this study, alopecia was successfully developed by DTX (10 mg/kg/three times) application. In the second stage of the study, application of HDDPiW-jSB solution, did not change the study parameters significantly on control group. The solution improved the anagen hair follicle count and Bcl-2 levels in the skin samples of DTX-induced alopecic rat groups, especially when applied twice weekly. Additionally, level of Caspase 3 was decreased. HDDPiW-jSB solution was safe when applied on the skin.ConclusionTopical HDDPiW-jSB solution could be effective and safe for the protection of DTX-induced alopecia in rat models.
Terbium-161 PSMA Therapy in mCRPC Patient Based on an Optimized Radiolabeling Protocol
(Springer, 2025-09) Sezgin, Ceren; Uygur, Emre; Parlak, Yasemin; Karatay, Busra; Barutca, Sabri; Dirican, Ahmet; Gumuser, Gul
This study presents a novel radiolabeling technique for [161Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [116 Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% +/- 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.